¼¼°èÀÇ ½Å°æ³»ºÐºñ¾Ï ½ÃÀå º¸°í¼­(2025³â)
Neuroendocrine Carcinoma Global Market Report 2025
»óǰÄÚµå : 1720838
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,240,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,019,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,799,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½Å°æ³»ºÐºñ¾Ï ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̸ç 2029³â±îÁö ¿¬Æò±Õ 7.3%ÀÇ ¼ºÀå·ü·Î 23¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº ¾Ï ¹ßº´·ü Áõ°¡, Á¦Ç° ½ÂÀηü Áõ°¡, ÷´Ü ¿µ»ó Áø´Ü¹ý äÅà Ȯ´ë, Ç¥Àû Ä¡·á È®´ë, Áø´Ü ¹× Ä¡·á ¿É¼ÇÀÇ °³¼± µîÀÌ °ßÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Áø´Ü ¹× ¿µ»ó ±â¼úÀÇ ¹ßÀü, Ç¥Àû Ä¡·á Á¢±Ù¹ý °³¹ß, ½Å°æ³»ºÐºñ Á¾¾ç °ü¸®ÀÇ Çõ½Å, Ç¥Àû Ä¡·á ¹× ¸é¿ª Ä¡·áÀÇ Áö¼ÓÀûÀÎ ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù.

Ç¥ÀûÄ¡·áÁ¦ÀÇ È®´ë´Â ½Å°æ³»ºÐºñ¾Ï ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç¥Àû Ä¡·áÁ¦´Â ƯÈ÷ ¾Ï¿¡¼­ Áúº´ ÁøÇàÀ» À¯¹ßÇÏ´Â ºÐÀÚ °úÁ¤À̳ª À¯ÀüÀÚ º¯À̸¦ ÆÄ±«Çϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. Ç¥ÀûÄ¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ƯÁ¤ À¯ÀüÀÚ µ¹¿¬º¯ÀÌ¿¡ ´ëÇÑ ³ôÀº Á¤È®¼º, °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ ¹ßÀü, ºÎÀÛ¿ëÀÌ Àû°í ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ´Ù´Â Á¡ µî¿¡ ±âÀÎÇÕ´Ï´Ù. ½Å°æ³»ºÐºñ¾Ï ¿¬±¸´Â Á¾¾çÀÇ À¯ÀüÀû, »ýÈ­ÇÐÀû ÇÁ·ÎÆÄÀÏ¿¡ µû¸¥ Ç¥Àû Ä¡·á¹ý °³¹ßÀ» ÃËÁøÇÏ¿© Ä¡·áÀÇ Á¤È®¼º°ú È¿´ÉÀ» Çâ»ó½Ãų °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 7¿ù ¹Ì±¹ À¯ÀüÀÚ ¹× ¼¼Æ÷Ä¡·áÇÐȸ(ASGCT)¿Í ¾¾Æ®¶óÀÎ(Citeline)Àº ÀÓ»ó 2»ó ½ÃÇè ÁßÀÎ À¯ÀüÀÚ Ä¡·áÁ¦ÀÇ ¼ö°¡ 2023³â 1ºÐ±â ¸» 247°³¿¡¼­ 2023³â 2ºÐ±â ¸» 260°³·Î 5% Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº Ç¥ÀûÄ¡·á Àü·«¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½Å°æ³»ºÐºñ¾Ï ½ÃÀåÀ» ÁÖµµÇϰí ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù.

½Å°æ³»ºÐºñ¾Ï ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº Ä¡·áÀÇ Á¤È®¼ºÀ» ³ôÀ̰í ȯÀÚ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ Ç¥Àû ¹æ»ç¼ºÀǾàǰ Ä¡·áÀÇ ¹ßÀü¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. Ç¥Àû ¹æ»ç¼ºÀǾàǰ Ä¡·á´Â °Ç°­ÇÑ Á¶Á÷¿¡ ´ëÇÑ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 ¾Ï¼¼Æ÷¿¡ ƯÀÌÀûÀ¸·Î ¹æ»ç¼±À» Á¶»çÇÏ´Â ¹æ»ç¼º ºÐÀÚ¸¦ »ç¿ëÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ij³ª´Ù¿¡ º»»ç¸¦ µÐ »ý¸í°øÇÐ ±â¾÷ ¾Ðµ¨¶ó Å×¶óǻƽ½º(Abdella Therapeutics)´Â 2024³â 9¿ù FDA·ÎºÎÅÍ ½Å°æ³»ºÐºñ¾Ï Ä¡·áÁ¦ ABD-147¿¡ ´ëÇÑ Èñ±ÍÀǾàǰ ÁöÁ¤À» ¹Þ¾Ò½À´Ï´Ù. ħ½À¼º ½Å°æ³»ºÐºñ¾Ï¿¡ ¸¹ÀÌ ¹ßÇöµÇ´Â DLL3 ´Ü¹éÁúÀ» ¹ßÇöÇÏ´Â Á¾¾çÀ» ¼±ÅÃÀûÀ¸·Î Ç¥ÀûÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. À̹ø ÁöÁ¤À¸·Î ABD-147Àº ÀÓ»ó½ÃÇè ¼¼¾× °øÁ¦ ¹× ÀáÀçÀû ½ÃÀå µ¶Á¡±Ç µî Áß¿äÇÑ ÀÌÁ¡À» Á¦°øÇϸç, ABD-147À» ¾Ï ºÐ¾ß¿¡¼­ À¯¸ÁÇÑ Ä¡·á ¿É¼ÇÀ¸·Î ÀÚ¸®¸Å±èÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª¹ÙÀÌ·¯½º ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Neuroendocrine carcinoma (NEC) is a rare and aggressive cancer that arises from neuroendocrine cells, which possess characteristics of both nerve cells and hormone-producing cells. It is diagnosed and treated to manage tumors that can develop in various organs, including the lungs, pancreas, and gastrointestinal tract, often requiring a combination of surgery, chemotherapy, and targeted therapies.

The primary types of neuroendocrine carcinoma include gastroenteropancreatic neuroendocrine tumors, carcinoid tumors, pheochromocytoma, and medullary thyroid carcinoma. Gastroenteropancreatic neuroendocrine tumors are rare malignancies that originate from neuroendocrine cells in the gastrointestinal tract or pancreas. Diagnosis involves various tools such as imaging, biopsy, and serology, while treatment options include chemotherapy, radiotherapy, surgery, and others. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, clinics, oncology centers, and ambulatory surgery centers.

The neuroendocrine carcinoma market research report is one of a series of new reports from The Business Research Company that provides neuroendocrine carcinoma market statistics, including the neuroendocrine carcinoma industry global market size, regional shares, competitors with the neuroendocrine carcinoma market share, detailed neuroendocrine carcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the neuroendocrine carcinoma industry. This neuroendocrine carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neuroendocrine carcinoma market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period was driven by the expansion of the imaging sector, a rising incidence of neuroendocrine tumors, increasing investments, government initiatives, and growing demand for treatments for neuroendocrine tumors.

The neuroendocrine carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period is expected to be driven by the rising incidence of cancer, an increasing rate of product approvals, greater adoption of advanced diagnostic imaging methods, the expansion of targeted therapies, and improved diagnosis and treatment options. Key trends include advancements in diagnostic and imaging technologies, the development of targeted treatment approaches, innovations in neuroendocrine tumor management, and continued progress in targeted therapies and immunotherapies.

The expansion of targeted therapies is expected to drive the growth of the neuroendocrine carcinoma market. Targeted therapies are designed to disrupt the molecular processes or genetic mutations responsible for disease progression, particularly in cancer. The increasing demand for targeted therapies is fueled by their precision in addressing specific genetic mutations, advancements in personalized medicine, and improved patient outcomes with fewer side effects. Neuroendocrine carcinoma research facilitates the development of targeted therapies that align with the tumor's genetic and biochemical profiles, enhancing treatment accuracy and effectiveness. For instance, in July 2023, the American Society of Gene & Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in Phase II clinical trials increased by 5%, from 247 at the end of Q1 2023 to 260 by the end of Q2 2023. This growth underscores the increasing focus on targeted treatment strategies, driving the neuroendocrine carcinoma market.

Leading companies in the neuroendocrine carcinoma market are focusing on advancements in targeted radiopharmaceutical therapy to enhance treatment precision and improve patient outcomes. Targeted radiopharmaceutical therapy uses radioactive molecules that specifically deliver radiation to cancer cells while minimizing damage to healthy tissue. For example, in September 2024, Abdera Therapeutics Inc., a Canada-based biotechnology company, received an orphan drug designation from the FDA for ABD-147 for the treatment of neuroendocrine carcinoma. ABD-147 is designed to selectively target tumors expressing the DLL3 protein, which is commonly upregulated in aggressive neuroendocrine cancers such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). This designation provides significant benefits, including tax credits for clinical trials and potential market exclusivity, positioning ABD-147 as a promising treatment option in the field of oncology.

In February 2024, Bristol-Myers Squibb Company, a US-based pharmaceutical company, acquired RayzeBio, Inc. for $4.1 billion. This acquisition aims to strengthen Bristol-Myers Squibb's oncology pipeline, particularly in neuroendocrine tumors and other difficult-to-treat cancers, by leveraging RayzeBio's expertise in targeted therapies and innovative drug development. RayzeBio Inc. is a US-based company specializing in the treatment of gastroenteropancreatic neuroendocrine tumors.

Major players in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.

North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroendocrine carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neuroendocrine carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuroendocrine carcinoma market consists of revenues earned by entities by providing services such as hormonal symptom management, long-term care plans, pain management, immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroendocrine carcinoma market also consists of sales of products including somatostatin analogs, positron emission tomography (PET) scanners, needles and equipment, infusion pumps, and drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuroendocrine Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuroendocrine carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for neuroendocrine carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuroendocrine carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Neuroendocrine Carcinoma Market Characteristics

3. Neuroendocrine Carcinoma Market Trends And Strategies

4. Neuroendocrine Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Neuroendocrine Carcinoma Growth Analysis And Strategic Analysis Framework

6. Neuroendocrine Carcinoma Market Segmentation

7. Neuroendocrine Carcinoma Market Regional And Country Analysis

8. Asia-Pacific Neuroendocrine Carcinoma Market

9. China Neuroendocrine Carcinoma Market

10. India Neuroendocrine Carcinoma Market

11. Japan Neuroendocrine Carcinoma Market

12. Australia Neuroendocrine Carcinoma Market

13. Indonesia Neuroendocrine Carcinoma Market

14. South Korea Neuroendocrine Carcinoma Market

15. Western Europe Neuroendocrine Carcinoma Market

16. UK Neuroendocrine Carcinoma Market

17. Germany Neuroendocrine Carcinoma Market

18. France Neuroendocrine Carcinoma Market

19. Italy Neuroendocrine Carcinoma Market

20. Spain Neuroendocrine Carcinoma Market

21. Eastern Europe Neuroendocrine Carcinoma Market

22. Russia Neuroendocrine Carcinoma Market

23. North America Neuroendocrine Carcinoma Market

24. USA Neuroendocrine Carcinoma Market

25. Canada Neuroendocrine Carcinoma Market

26. South America Neuroendocrine Carcinoma Market

27. Brazil Neuroendocrine Carcinoma Market

28. Middle East Neuroendocrine Carcinoma Market

29. Africa Neuroendocrine Carcinoma Market

30. Neuroendocrine Carcinoma Market Competitive Landscape And Company Profiles

31. Neuroendocrine Carcinoma Market Other Major And Innovative Companies

32. Global Neuroendocrine Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuroendocrine Carcinoma Market

34. Recent Developments In The Neuroendocrine Carcinoma Market

35. Neuroendocrine Carcinoma Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â